

ITL BioMedical Awarded Supply Agreement with New Zealand Blood Service for SSK

[ITL BioMedical](#), a division of [ITL Health Group](#) (ASX:ITD), that sets industry standards for the innovative design and production of biological sampling systems, is pleased to announce it has signed a two year supply agreement, with possible ongoing renewals, for its SampLok Sampling Kit (SSK) with New Zealand Blood Service ([NZBS](#)).

NZBS, the provider of blood services for New Zealand, provides the public with safe, appropriate and timely access to blood and tissue products and related services.

ITL BioMedical is a growing provider of specialty ancillary products for the blood culture testing market, estimated to be worth US\$3.3b in 2016 and growing to US\$4.8b by 2021⁽¹⁾. The NZBS contract builds on increased global SSK sales in 2016 when ITL signed many new contracts and a Global Distribution Agreement with bioMérieux, a multinational biotechnology company.

SSK is a highly innovative product that is utilized in the blood banking market to transfer platelet samples during bacterial detection testing. SSK offers state of the art product design that facilitates product sampling for laboratory testing process efficiencies, safety in reducing potential for needlestick injuries and reduced biohazard waste, among other benefits.

“It is good to see ITL BioMedical’s worldwide sales of SSK continue to grow after a very positive 2016. We look forward to seeing this continue as they take advantage of the significant growth forecast for the blood culture testing market” commented Bill Mobbs, Executive Chairman of ITL Health Group.

Bill Mobbs
Executive Chairman

(1) www.marketsandmarkets.com/PressReleases/blood-culture-test.as

ITL Health Group

ITL is an innovative global medical technology company made up of four divisions; ITL BioMedical, ITL Healthcare, ITL Clinical & MyHealthTest.

ITL creates & manufactures leading edge medical devices for the clinical, blood banking, & laboratory markets & is a growing provider of specialist ancillary products for the blood culture testing market.

ITL holds an IP portfolio of 48 patents & sells into 55 countries.

MyHealthTest creates and markets highly innovative direct to consumer pathology testing for major chronic diseases.



Ranked 16th most Innovative Company by the
AFR Innovative Companies Awards

Australian Securities Exchange
Code: ITD

Ordinary Shares
95,928,314

Board of Directors

Bill Mobbs	Executive Chairman
Mark Peatey	Non-executive Director
Andrew Turnbull	Non-executive Director
Trevor Doolan	Chief Financial Officer & Company Secretary

ITL Contact
Trevor Doolan Company Secretary
Phone: +61 3 8773 3050
Email: info@itl-limited.com
Address Unit 1, 63 Wells Road
 Chelsea Heights,
 Victoria, 3196

www.itlhealthgroup.com

Media
Walbrook IR Ben Knowles
Phone: +61 426 277 760
Email: ben.knowles@walbrookir.co.au

About New Zealand Blood Service - nzblood.co.nz

New Zealand Blood Service (NZBS) was created on 1 July 1998. NZBS takes the responsibility for the development of an integrated national blood transfusion process from the collection of blood from volunteer donors to the transfusion of blood products within the hospital environment - a 'vein to vein' transfusion service.

About ITL BioMedical - ITLBioMedical.com

ITL BioMedical is a division of ITL Health Group that sets industry standards for the innovative design and production of biological sampling systems for human and animal use. The Division's patented medical devices focus on safety and process efficiency for end-users and their blood donors and patients in healthcare markets worldwide.